Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning, and welcome to Johnson & ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations ...

Johnson has also claimed that the Great Depression was "pretty well planned," adding he knew it sounds like a conspiracy theory. In his interview with Benny Johnson, the senator said he knew they ...

Selma Blair spoke very candidly to PEOPLE about her health following her multiple sclerosis diagnosis while attending The ...

a treatment for bipolar disorder and depression. Management said they now expect sales of $92 billion this year, up from a previous forecast of $91.3 billion. Johnson & Johnson’s cash flow.

Probiotics may help improve a person's daily mood and, if taken regularly for about 2 weeks, could help reduce negative ...

Further, it provides a sense of dignity and self-worth for patients by giving them a sense of making a valuable contribution.

Two years after a 10-year-old took his own life in Marion County, his parents are suing the district because they say a teacher bullied him ...